Dilated Cardiomyopathy in Dogs: Welfare and Management

Canine dilated cardiomyopathy is a serious heart disease affecting large breeds. This guide covers welfare impacts, management, and quality of life.

Key Facts

DCM involves weakening and dilation of the heart muscle reducing pumping efficiency
Large breeds (Dobermanns, Great Danes, Irish Wolfhounds) are most affected
Dobermanns commonly develop occult DCM before developing clinical signs
Signs include exercise intolerance, coughing, breathing difficulty, and collapse
Treatment with pimobendan, ACE inhibitors, and diuretics improves quality of life
Cardiac arrhythmias increase the risk of sudden death

Welfare Considerations and Management

Welfare-centred DCM management involves cardioprotective medications at pre-clinical stage (pimobendan in Dobermanns with occult DCM) and full heart failure treatment when clinical signs develop. Pimobendan, ACE inhibitors, spironolactone, and diuretics (frusemide) form the standard treatment protocol. Managing concurrent arrhythmias reduces sudden death risk. Regular monitoring guides treatment adjustments. Quality of life assessment guides decisions about treatment escalation and end-of-life care.

What You Can Do

Screen Dobermanns annually for DCM with echocardiography and Holter monitoring
Begin pimobendan treatment at the pre-clinical stage as recommended by cardiologists
Monitor closely for signs of worsening heart failure (increased respiratory rate at rest)
Discuss quality of life openly with your cardiologist throughout the disease journey